Naia Pharmaceuticals Status
The company raised an undisclosed amount of funding from Cedars-Sinai on April 3, 2017.
Operator of a biopharmaceutical company created to develop drugs for Short Bowel Syndrome. The company develops clinically advance drug candidates for Short Bowel Syndrome (SBS) and other rare gastrointestinal diseases enabling health care providers to treat gastrointestinal problems and disorders and reduce recovery times.
Year Founded
2014
General Information
-
Website
-
Business Status
Startup
-
Ownership Status
Privately Held (backing)
-
Financing Status
Angel-Backed
Naia Pharmaceuticals News and Updates
The usual slow grind
Philstar.com | October 25, 2023
Shaping the future
Philstar.com | October 21, 2023
2023 Rawlings Gold Glove Award® Finalists Announced
PR Newswire | October 18, 2023
Medical, pharma sectors warn of challenges
The Manila Times | October 11, 2023
JICA funding for Philippines transport reaches P1.5 trillion
Philstar.com | September 30, 2023
Fernando Zobel returns as AC Health chair
Philstar.com | September 27, 2023
Naia Pharmaceuticals Primary Industry Sector / Group / Code
Naia Pharmaceuticals's Trends
Headquarters
-
HQ CitySan Francisco
-
HQ State/ProvinceCalifornia
-
HQ CountryUnited States
Naia Pharmaceuticals's Keywords
mood_badFeed is empty.
Add a review